Skip to Content
Merck
All Photos(1)

Documents

A-008

Supelco

S(+)-Amphetamine (dextro-Amphetamine) solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

dextro-Amphetamine

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C9H13N
CAS Number:
51-64-9
Molecular Weight:
135.21
MDL number:
MFCD00133300
UNSPSC Code:
41116107
PubChem Substance ID:
329770571
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

SNAP-N-SPIKE®. SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

forensics and toxicology

format

single component solution

storage temp.

−20°C

SMILES string

C[C@H](N)Cc1ccccc1

InChI

1S/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1

InChI key

KWTSXDURSIMDCE-QMMMGPOBSA-N

Gene Information

human ... SLC18A2(6571)

General description

Amphetamine is a stimulant of the phenethylamine class found in ADHD-treatment drugs such as Adderall®, Vyvanse®, and ProCentra®. Because of its stimulant effect, amphetamine is used recreationally as a performance-enhancer and illicit drug. This Certified Snap-N-Spike® Solution is suitable for use in urine drug testing, clinical toxicology, forensic analysis, and isomer identification by LC-MS/MS or GC/MS.

Application


  • Determination of amphetamine enantiomers in urine by conductive vial electromembrane extraction and ultra-high performance supercritical fluid chromatography tandem mass spectrometry: This study illustrates the advanced analytical methodologies employed to differentiate the enantiomers of amphetamine, demonstrating the high specificity and sensitivity required for forensic and clinical toxicology. The research highlights the utility of high-purity S(+)-amphetamine standards in improving the accuracy of drug monitoring and abuse detection (Skaalvik TG et al., 2023).

Legal Information

Adderall is a registered trademark of Richwood Pharmaceutical Company, Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
ProCentra is a registered trademark of Outlook Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Vyvanse is a registered trademark of Shire, LLC

related product

Product No.
Description
Pricing

A-016

(±)-Amphetamine-d11 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-050

Amine Mixture-6 solution, 250 μg/mL each component in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-002

(±)-Amphetamine-d5 (deuterium label on ring) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-005

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-007

(±)-Amphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-013

(±)-Amphetamine-d5 (deuterium label on side chain) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-017

(±)-Amphetamine-d8 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-018

(±)-Amphetamine-d8 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-019

(±)-Amphetamine-d11 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-044

(±)-Amphetamine-d6 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-045

(±)-Amphetamine-d6 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-049

R(-)-Amphetamine (levo-Amphetamine), 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

E-018

(±)-N-Ethylamphetamine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

L-026

Lisdexamfetamine dimesylate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

L-028

Lisdexamfetamine-D4 dimesylate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-050

PMA hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

A-212

(±)-Amphetamine-13C6 hydrochloride solution, 100 μg/mL in methanol ((as free base)), certified reference material, ampule of 1 mL, Cerilliant®

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M L J Schouw et al.
NeuroImage, 72, 1-9 (2013-01-09)
Pharmacological magnetic resonance imaging (phMRI) maps the neurovascular response to a pharmacological challenge and is increasingly used to assess neurotransmitter systems. Here we investigated the hemodynamic response to a dopaminergic (DAergic) challenge with dextroamphetamine (dAMPH) in humans using arterial spin
Joel L Young
Postgraduate medicine, 125(1), 162-168 (2013-02-09)
Fatigue is commonly reported in the primary care setting; however, its cause is often unclear. This article presents 3 cases involving patients with chronic fatigue syndrome who responded poorly to treatment. After clinical evaluation, all patients were found to meet
Greg W Mattingly et al.
BMC psychiatry, 13, 39-39 (2013-01-30)
Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of
Sanders A McDougall et al.
Pharmacology, biochemistry, and behavior, 104, 154-162 (2013-01-31)
The early ontogeny of D-amphetamine-induced one-trial behavioral sensitization was characterized using male and female preweanling and preadolescent rats. In Experiment 1, rats were injected with saline or D-amphetamine (1, 4, or 8mg/kg) in activity chambers or the home cage on
J H Check et al.
Clinical and experimental obstetrics & gynecology, 40(2), 284-285 (2013-08-27)
Sympathetic nervous system hypofunction has been found to be associated with motility disorders of the bowel, including gastroparesis, pseudointestinal obstruction, and esophageal motility disorders. These disorders respond to sympathomimetic amine therapy. The purpose of this study was to see if
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service